Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation

Transplantation

Volumn 70, Issue 4, 2000, Pages 617-625

  Jain, Ashok ^a   Mazariegos, George ^a   Kashyap, Randeep ^a   Green, Mike ^a   Gronsky, Cindy ^a   Starzl, Thomas E ^a   Fung, John ^a   Reyes, Jorge ^a,b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; OKT 3; PREDNISONE; STEROID; TACROLIMUS;

ADOLESCENT; ARTICLE; CHILD; DRUG EFFECT; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; PEDIATRIC SURGERY; PRIORITY JOURNAL; RETREATMENT; STEROID THERAPY; TREATMENT OUTCOME;

EID: 0034721325     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200008270-00015     Document Type: Article

References (37)

1. Pediatric transplantation
2. Update of pediatric liver transplantation
3. 10 years of pediatric liver transplantation
4. Comparison of cyclosporine- vs tacrolimus-based immunosuppression in pediatric liver transplantation
5. Pediatric liver transplantation
6. Pediatric liver transplantation
7. FK 506 for liver, kidney, pancreas transplantation.Lancet
8. Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications
9. Conversion of liver allograftrecipients from cyclosporine to FK 506-based immunosuppression: Benefits and pitfalls
10. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy: A clinicopathologic study of 96 patients
11. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation a report of the U.S. Multicenter Liver Study Group
12. The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation
13. Anonymous. Randomised trial comparing tacrolimus (FK506)and cyclosporin in prevention of liver allograft rejection Group
14. Anonymous. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation
15. Useof FK 506 in pediatric patients
16. Early trials with FK 506 as primary treatment inliver transplantation
17. Incidence and treatment ofrejection episodes in primary orthotopic liver transplantation under FK 506
18. Two-year experience with FK 506in pediatric patients
19. Tacrolimus (FK506): The pros and cons of itsuse as an immunosuppressant in pediatric liver transplantation
20. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation Results from the U.S. Multicenter Trial
21. The use of tacrolimus in pediatric liver transplantation
22. Assay of FK506 in plasma
23. A whole blood FK506 assay for the IMx analyzer
24. Practicalaspects of FK 506 analysis (Pittsburgh experience)
25. Cyclosporine measurement by FPIA, PC-RIA and HPLC following liver transplantation
26. FK 506 versus cyclosporine inpediatric liver transplantation
27. Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations
28. Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients
29. The Neoral formulation: Improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients
30. A new oral formulationof cyclosporine for early oral immunosuppressive therapy in liver transplant recipients
31. Long-term outcomes in pediatric liver recipients: Comparison between cyclosporin A and tacrolimus
32. Single-center experience withprimary orthotopic liver transplantation with FK 506 immunosuppression
33. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients
34. Weaning of immunosuppression in liver transplant recipients
35. Otto GGlucose metabolism following liver transplantation and immunosuppression with cyclosporine A or FK 506
36. Postoperative glucose metabolism in liver transplant recipients. A two-year prospective randomized study of cyclosporine versus FK506
37. Management of post-transplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy